TESARO Summarizes TSR-042 Clinical Data Presented at AACR

World News: . []

CHICAGO April 16 2018 GLOBE NEWSWIRE -- TESARO, Inc NASDAQTSRO an oncology-focused biopharmaceutical company today summarized initial data from the Phase 1 GARNET trial of TSR-042 anti-PD-1 antibody) in patients with microsatellite inst ability...

More news and information about TESARO, Inc.

Published By:

Globe Newswire: 14:00 GMT Monday 16th April 2018

Published: .

Search for other references to "tesaro" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us